SutroVax rais­es $64M with plans to chal­lenge Pfiz­er’s megablock­buster Pre­vnar 13 for the heavy­weight ti­tle in vac­cines

When SutroVax was spun out of Sutro about four years ago, the biotech took along a con­ju­ga­tion plat­form that was re­pur­posed for de­vel­op­ing a new brand of vac­cines. And now that they are aim­ing for the clin­ic with a lead pneu­mo­coc­cal vac­cine, SutroVax has reeled in a whop­ping $64 mil­lion raise to get them well in­to hu­man stud­ies for a new vac­cine that will chal­lenge the megablock­buster Pre­vnar 13 for the heavy­weight ti­tle in its field.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.